Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

Rozanov DV, Rozanov ND, Chiotti KE, Reddy A, Wilmarth PA, David LL, Cha SW, Woo S, Pevzner P, Bafna V, Burrows GG, Rantala JK, Levin T, Anur P, Johnson-Camacho K, Tabatabaei S, Munson DJ, Bruno TC, Slansky JE, Kappler JW, Hirano N, Boegel S, Fox BA, Egelston C, Simons DL, Jimenez G, Lee PP, Gray JW, Spellman PT.

J Proteomics. 2018 Mar 30;176:13-23. doi: 10.1016/j.jprot.2018.01.004. Epub 2018 Jan 10.

2.

Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR.

Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, Nakano TA, Simons DL, Jimenez G, Yim JH, Rozanov DV, Falta MT, Fontenot AP, Reynolds PR, Leach SM, Borges VF, Kappler JW, Spellman PT, Lee PP, Slansky JE.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8272-7. doi: 10.1073/pnas.1606994113. Epub 2016 Jun 15.

3.

Systemic effects of TRAIL (TNF-related apoptosis-inducing ligand) during acute γ-irradiation.

Arkhipova EN, Alchinova IB, Cherepov AB, Rozanov DV, Medvedeva YS, Karganov MY.

Bull Exp Biol Med. 2014 Feb;156(4):452-6. doi: 10.1007/s10517-014-2372-9. Epub 2014 Mar 5.

PMID:
24771425
4.

Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Remacle AG, Shiryaev SA, Radichev IA, Rozanov DV, Stec B, Strongin AY.

J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.

5.

Internal cleavages of the autoinhibitory prodomain are required for membrane type 1 matrix metalloproteinase activation, although furin cleavage alone generates inactive proteinase.

Golubkov VS, Cieplak P, Chekanov AV, Ratnikov BI, Aleshin AE, Golubkova NV, Postnova TI, Radichev IA, Rozanov DV, Zhu W, Motamedchaboki K, Strongin AY.

J Biol Chem. 2010 Sep 3;285(36):27726-36. doi: 10.1074/jbc.M110.135442. Epub 2010 Jul 6.

6.

Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.

Sounni NE, Rozanov DV, Remacle AG, Golubkov VS, Noel A, Strongin AY.

Int J Cancer. 2010 Mar 1;126(5):1067-78. doi: 10.1002/ijc.24690. Erratum in: Int J Cancer. 2010 Apr 15;126(8):2002.

7.

Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.

Rozanov DV, Savinov AY, Golubkov VS, Rozanova OL, Postnova TI, Sergienko EA, Vasile S, Aleshin AE, Rega MF, Pellecchia M, Strongin AY.

Mol Cancer Ther. 2009 Jun;8(6):1515-25. doi: 10.1158/1535-7163.MCT-09-0202. Epub 2009 Jun 9.

8.

Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.

Radichev IA, Remacle AG, Sounni NE, Shiryaev SA, Rozanov DV, Zhu W, Golubkova NV, Postnova TI, Golubkov VS, Strongin AY.

Biochem J. 2009 Apr 28;420(1):37-47. doi: 10.1042/BJ20090082.

9.

Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer.

Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S, Strongin AY.

Cancer Res. 2008 Jun 1;68(11):4086-96. doi: 10.1158/0008-5472.CAN-07-6458.

10.

Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism.

D'Alessio S, Ferrari G, Cinnante K, Scheerer W, Galloway AC, Roses DF, Rozanov DV, Remacle AG, Oh ES, Shiryaev SA, Strongin AY, Pintucci G, Mignatti P.

J Biol Chem. 2008 Jan 4;283(1):87-99. Epub 2007 Nov 8.

11.
12.

Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells.

Golubkov VS, Chekanov AV, Savinov AY, Rozanov DV, Golubkova NV, Strongin AY.

Cancer Res. 2006 Nov 1;66(21):10460-5.

13.
14.
15.

Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP.

Remacle AG, Rozanov DV, Fugere M, Day R, Strongin AY.

Oncogene. 2006 Sep 14;25(41):5648-55. Epub 2006 Apr 24.

PMID:
16636666
16.

O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP).

Remacle AG, Chekanov AV, Golubkov VS, Savinov AY, Rozanov DV, Strongin AY.

J Biol Chem. 2006 Jun 23;281(25):16897-905. Epub 2006 Apr 20.

17.

Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.

Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY.

Cancer Res. 2006 Mar 1;66(5):2716-24.

18.

Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies.

Johnson SL, Jung D, Forino M, Chen Y, Satterthwait A, Rozanov DV, Strongin AY, Pellecchia M.

J Med Chem. 2006 Jan 12;49(1):27-30.

19.

Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency.

Chekanov AV, Remacle AG, Golubkov VS, Akatov VS, Sikora S, Savinov AY, Fugere M, Day R, Rozanov DV, Strongin AY.

Arch Biochem Biophys. 2006 Feb 1;446(1):52-9. Epub 2005 Dec 7.

PMID:
16384550
20.

Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase.

Shiryaev SA, Ratnikov BI, Chekanov AV, Sikora S, Rozanov DV, Godzik A, Wang J, Smith JW, Huang Z, Lindberg I, Samuel MA, Diamond MS, Strongin AY.

Biochem J. 2006 Jan 15;393(Pt 2):503-11.

21.

The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP).

Remacle AG, Rozanov DV, Baciu PC, Chekanov AV, Golubkov VS, Strongin AY.

J Cell Sci. 2005 Nov 1;118(Pt 21):4975-84. Epub 2005 Oct 11.

22.

Efficient synthetic inhibitors of anthrax lethal factor.

Forino M, Johnson S, Wong TY, Rozanov DV, Savinov AY, Li W, Fattorusso R, Becattini B, Orry AJ, Jung D, Abagyan RA, Smith JW, Alibek K, Liddington RC, Strongin AY, Pellecchia M.

Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9499-504. Epub 2005 Jun 27.

23.

Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas.

Savinov AY, Rozanov DV, Golubkov VS, Wong FS, Strongin AY.

J Biol Chem. 2005 Jul 29;280(30):27755-8. Epub 2005 Jun 8.

24.

Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability.

Golubkov VS, Boyd S, Savinov AY, Chekanov AV, Osterman AL, Remacle A, Rozanov DV, Doxsey SJ, Strongin AY.

J Biol Chem. 2005 Jul 1;280(26):25079-86. Epub 2005 May 4.

25.

Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin.

Li W, Savinov AY, Rozanov DV, Golubkov VS, Hedayat H, Postnova TI, Golubkova NV, Linli Y, Krajewski S, Strongin AY.

Cancer Res. 2004 Dec 1;64(23):8657-65.

26.

Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system.

Rozanov DV, Savinov AY, Golubkov VS, Postnova TI, Remacle A, Tomlinson S, Strongin AY.

J Biol Chem. 2004 Nov 5;279(45):46551-7. Epub 2004 Sep 14.

27.
28.

Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q.

Rozanov DV, Sikora S, Godzik A, Postnova TI, Golubkov V, Savinov A, Tomlinson S, Strongin AY.

J Biol Chem. 2004 Nov 26;279(48):50321-8. Epub 2004 Sep 16.

29.

Prointegrin maturation follows rapid trafficking and processing of MT1-MMP in Furin-Negative Colon Carcinoma LoVo Cells.

Deryugina EI, Ratnikov BI, Yu Q, Baciu PC, Rozanov DV, Strongin AY.

Traffic. 2004 Aug;5(8):627-41.

30.

Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane type-1 matrix metalloproteinase in malignant cells.

Rozanov DV, Deryugina EI, Monosov EZ, Marchenko ND, Strongin AY.

Exp Cell Res. 2004 Feb 1;293(1):81-95.

PMID:
14729059
31.

The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells.

Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY.

J Biol Chem. 2004 Feb 6;279(6):4260-8. Epub 2003 Nov 25.

33.
34.

The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR.

Rozanov DV, Ghebrehiwet B, Postnova TI, Eichinger A, Deryugina EI, Strongin AY.

J Biol Chem. 2002 Mar 15;277(11):9318-25. Epub 2001 Dec 31.

35.

An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase.

Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, Chestukhina GG, Smith JW, Deryugina EI, Strongin AY.

J Biol Chem. 2002 Mar 1;277(9):7377-85. Epub 2001 Dec 10.

36.
37.

Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin.

Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY.

Biochem J. 2001 Jun 15;356(Pt 3):705-18.

39.

RecA-independent pathways of lambdoid prophage induction in Escherichia coli.

Rozanov DV, D'Ari R, Sineoky SP.

J Bacteriol. 1998 Dec;180(23):6306-15.

Supplemental Content

Loading ...
Support Center